Showing 1,097 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Pharmaceutical industry

Healthcare: The race to cure rising drug costs

Editor's pick
Financial Times
13 February 2015
Access to healthcare

UNITAID: 2015 Hepatitis C medicines technology and market landscape

Editor's pick
UNITAID
13 February 2015
Hepatitis C treatment

Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

Editor's pick
Reuters
13 February 2015
Hepatitis C treatment

Gilead expects big increase in Europeans treated with hep C drug

Editor's pick
Reuters
11 February 2015
Hepatitis C symptoms & diagnosis

Strategies for Slowing the Progression of Liver Fibrosis in Hepatitis C

Editor's pick
HCP Live
11 February 2015
Hepatitis C treatment

A more personalised approach to hepatitis C treatment may improve adherence and completion rates

News
11 February 2015
Access to healthcare

Gilead faces challenge to European patent on pricey hep C drug

Editor's pick
Reuters
10 February 2015
Hepatitis C treatment

Worldwide treatment of hepatitis C could be within sight at the right cost

Editor's pick
Imperial College press release
9 February 2015
Access to healthcare

Portugal agrees to treat 13,000 hepatitis C patients

Editor's pick
Xinhua
9 February 2015
Hepatitis C treatment

What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean

Editor's pick
Wall Street Journal (blog)
5 February 2015
Hepatitis C treatment

Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion

Editor's pick
New York Times
5 February 2015
Finance & funding

How Hepatitis C Is Shining A Light On Critical Gaps In Payment Reform

Editor's pick
Health Affairs (blog)
4 February 2015
Access to healthcare

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

Editor's pick
TAG
3 February 2015
Hepatitis C treatment

German insurers win discounts on Gilead's Sovaldi

Editor's pick
Yahoo News
26 January 2015
Hepatitis C treatment

Merck discontinues Victrelis (boceprevir) voluntarily in the United States

Editor's pick
EATG
21 January 2015
Hepatitis C treatment

Gilead and AbbVie take hepatitis C battle to Europe

Editor's pick
Financial Times (free registration required)
20 January 2015
Hepatitis C treatment

The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies

Editor's pick
The Body Pro
19 January 2015
Access to healthcare

Hepatitis C drug delayed by NHS due to high cost

Editor's pick
The Guardian
16 January 2015
Hepatitis C treatment

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

Editor's pick
AbbVie press release
16 January 2015
Hepatitis C treatment

How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

Editor's pick
The Motley Fool
15 January 2015
Hepatitis C treatment

India rejects Gilead's Hepatitis C drug patent request

Editor's pick
Reuters
14 January 2015
Hepatitis C symptoms & diagnosis

Doctors Question Wider Hepatitis C Screening Despite Cures

Editor's pick
Bloomberg
14 January 2015
Hepatitis C treatment

US: Prime Therapeutics breaks from competition, strikes deals to prefer both Harvoni, Viekira hepatitis C drugs

Editor's pick
Prime Therapeutics press release
13 January 2015
Access to healthcare

Spaniards rally over hepatitis C drugs

Editor's pick
Press TV
12 January 2015